Frederic Commo
Overview
Explore the profile of Frederic Commo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
1790
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Friboulet L, Postel-Vinay S, Sourisseau T, Adam J, Stoclin A, Ponsonnailles F, et al.
Cell Cycle
. 2013 Sep;
12(20):3298-306.
PMID: 24036546
ERCC1 (excision repair cross-complementation group 1) plays essential roles in the removal of DNA intrastrand crosslinks by nucleotide excision repair, and that of DNA interstrand crosslinks by the Fanconi anemia...
12.
Alsafadi S, Even C, Falet C, Goubar A, Commo F, Scott V, et al.
Clin Breast Cancer
. 2013 Jul;
13(5):401-8.
PMID: 23830798
Background: Molecular segmentation of breast cancer allows identification of small groups of patients who present high sensitivity to targeted agents. A patient, with chemo- and trastuzumab-resistant HER2-overexpressing breast cancer, who...
13.
Broutin S, Commo F, De Koning L, Marty-Prouvost B, Lacroix L, Talbot M, et al.
Thyroid
. 2013 Jul;
PMID: 23822199
Background: Medullary thyroid carcinoma (MTC) is a rare tumor that is due to activating mutations in the proto-oncogene RET. Vandetanib, a tyrosine-kinase inhibitor, has been recently approved to treat adult...
14.
Prada N, Antoni G, Commo F, Rusakiewicz S, Semeraro M, Boufassa F, et al.
Oncoimmunology
. 2013 Jun;
2(3):e23472.
PMID: 23802087
Natural killer (NK) cells play a prominent role at the intersection between innate and cognate immunity, thus influencing the development of multiple pathological conditions including HIV-1-induced AIDS. Not only NK...
15.
Ferte C, Trister A, Huang E, Bot B, Guinney J, Commo F, et al.
Clin Cancer Res
. 2013 Jun;
19(16):4315-25.
PMID: 23780890
The progressive introduction of high-throughput molecular techniques in the clinic allows for the extensive and systematic exploration of multiple biologic layers of tumors. Molecular profiles and classifiers generated from these...
16.
Vanhecke E, Valent A, Tang X, Vielh P, Friboulet L, Tang T, et al.
Clin Lung Cancer
. 2013 Jun;
14(5):549-57.
PMID: 23773262
Background: Excision repair cross complementing 1 gene expression level has potential as a prognostic and predictive marker of the efficacy of chemotherapy in NSCLC. The effect of ERCC1 gene copy...
17.
Ferte C, Loriot Y, Clemenson C, Commo F, Gombos A, Bibault J, et al.
Mol Cancer Ther
. 2013 May;
12(7):1213-22.
PMID: 23640142
Insulin-like growth factor receptor-1 (IGF-1R) inhibition could be a relevant therapeutic approach in small cell lung cancer (SCLC) given the importance of an IGF-1R autocrine loop and its role in...
18.
Vignot S, Frampton G, Soria J, Yelensky R, Commo F, Brambilla C, et al.
J Clin Oncol
. 2013 May;
31(17):2167-72.
PMID: 23630207
Purpose: Characterization of the genomic changes that drive an individual patient's disease is critical in management of many cancers. In patients with non-small-cell lung cancer (NSCLC), obtaining tumor samples of...
19.
Rusakiewicz S, Semeraro M, Sarabi M, Desbois M, Locher C, Mendez R, et al.
Cancer Res
. 2013 Apr;
73(12):3499-510.
PMID: 23592754
Cancer immunosurveillance relies on effector/memory tumor-infiltrating CD8(+) T cells with a T-helper cell 1 (TH1) profile. Evidence for a natural killer (NK) cell-based control of human malignancies is still largely...
20.
Friboulet L, Olaussen K, Pignon J, Shepherd F, Tsao M, Graziano S, et al.
N Engl J Med
. 2013 Mar;
368(12):1101-10.
PMID: 23514287
Background: The excision repair cross-complementation group 1 (ERCC1) protein is a potential prognostic biomarker of the efficacy of cisplatin-based chemotherapy in non-small-cell lung cancer (NSCLC). Although several ongoing trials are...